What question did this study set out to answer?

To evaluate the association between BSA-adjusted bevacizumab dosing and patient outcomes in unresectable HCC.

May 8, 2026

Optimizing bevacizumab exposure in atezolizumab-based therapy for unresectable hepatocellular carcinoma: A nationwide real-world study

Puntos clave

To evaluate the association between BSA-adjusted bevacizumab dosing and patient outcomes in unresectable HCC.
Retrospective study of 1,507 unresectable HCC patients treated with Atezo/Bev across 30 institutions in Japan.
Analysis of the bevacizumab-BSA index (BBI) to determine its relationship with survival outcomes.
Patients classified into Under, Target, and Over BBI groups based on their dosage ratios.
The Target BBI group showed a median progression-free survival (PFS) of 10.3 months versus 6.5 months in non-Target (p <0.001).
The median overall survival (OS) for the Target group was 24.9 months compared to 19.2 months for non-Target (p =0.008).
Objective response rate in the Target group was significantly higher (p =0.023) with no significant differences in adverse events across groups.

Resumen

Background 95% confidence interval CI, 0.715–0.910; p <0.001) and OS (HR, 0.850; 95% CI, 0.733–0.985; p =0.031). The objective response rate was significantly higher in the Target group ( p =0.023), while treatment-related adverse event rates were comparable across the BBI groups, with no significant differences in proteinuria, hypertension, or other toxicities. Conclusions: BSA-adjusted bevacizumab dosing was associated with improved efficacy without increased toxicity in patients with unresectable HCC treated with Atezo/Bev.

Me gusta

Guardar

Cite This Study

Aoe et al. (Wed,) studied this question.

synapsesocial.com/papers/69fd7f86bfa21ec5bbf08118 https://doi.org/https://doi.org/10.1097/hep.0000000000001781

Me gusta

Guardar